Treatment of HIV infection: the antiretroviral nucleoside analogues. Nucleoside analogues: monotherapy.
At present, the nucleoside analogues are the cornerstone of therapy for HIV infection. Of the three that have been approved for clinical use, AZT is the only one that has clearly proved to prolong survival. ddI is indicated for patients who develop toxicity or resistance to AZT. Current data do not support ddC monotherapy as first-line treatment.
Skowron
G
G
Brown University.
D000163:Acquired Immunodeficiency Syndrome / Q000188:drug therapy; D000998:Antiviral Agents / Q000627:therapeutic use*; D016049:Didanosine / Q000008:administration & dosage / Q000037:antagonists & inhibitors; D004352:Drug Resistance, Microbial; D015658:HIV Infections / Q000188:drug therapy*; D015497:HIV-1 / Q000187:drug effects*; D006801:Humans; D013997:Time Factors; D016047:Zalcitabine / Q000008:administration & dosage; D015215:Zidovudine / Q000008:administration & dosage / Q000037:antagonists & inhibitors
D000998:Antiviral Agents; D015215:Zidovudine; D016047:Zalcitabine; D016049:Didanosine